Heterologous Antibody Responses of Calves to Anaplasma centrale ans A. marginale

ABSTRACTPreparedness against an A/H5N1 influenza pandemic requires well-tolerated, effective vaccines which provide both vaccine strain-specific and heterologous, cross-clade protection. This study was conducted to assess the immunogenicity and safety profile of an MF59-adjuvanted, prepandemic influenza vaccine containing A/turkey/Turkey/01/2005 (H5N1) strain viral antigen. A total of 343 participants, 194 adults (18 to 60 years) and 149 elderly individuals (≥61 years), received two doses of the investigational vaccine given 3 weeks apart. Homologous and heterologous antibody responses were analyzed by hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization (MN) assays 3 weeks after administration of the first vaccine dose and 3 weeks and 6 months after the second dose. Immunogenicity was assessed according to European licensure criteria for pandemic influenza vaccines. After two vaccine doses, all three European licensure criteria were met for adult and elderly subjects against the homologous vaccine strain, A/turkey/Turkey/1/2005, when analyzed by HI and SRH assays. Cross-reactive antibody responses were observed by HI and SRH analyses against the heterologous H5N1 strains, A/Indonesia/5/2005 and A/Vietnam/1194/2004, in adult and elderly subjects. Solicited local and systemic reactions were mostly mild to moderate in severity and occurred less frequently in the elderly than in adult vaccinees. In both adult and elderly subjects, MF59-adjuvanted vaccine containing 7.5 μg of A/Turkey strain influenza virus antigen was highly immunogenic, well tolerated, and able to elicit cross-clade, heterologous antibody responses against A/Indonesia and A/Vietnam strains 6 weeks after the first vaccination.

Download Full-text

Genotypic and pathogenic characterization of genotype VII Newcastle disease viruses isolated from commercial farms in Egypt and evaluation of heterologous antibody responses

Archives of Virology ◽

10.1007/s00705-017-3336-y ◽

2017 ◽

Vol 162 (7) ◽

pp. 1985-1994 ◽

Cited By ~ 8

Author(s):

A. M. Saad ◽

Ahmed Samy ◽

M. A. Soliman ◽

A. Arafa ◽

A. Zanaty ◽

...

Keyword(s):

Newcastle Disease ◽

Antibody Responses ◽

Commercial Farms ◽

Genotype Vii ◽

Heterologous Antibody

Download Full-text

Homologous and heterologous antibody responses to subunit influenza virus vaccine

Journal of Hygiene ◽

10.1017/s0022172400025201 ◽

1978 ◽

Vol 81 (3) ◽

pp. 331-336 ◽

Cited By ~ 3

Author(s):

Brian J. Feery ◽

M. G. Evered ◽

Kathleen Hayes

Keyword(s):

Influenza Virus ◽

Hong Kong ◽

Virus Vaccine ◽

Geometric Mean ◽

Influenza Virus Vaccine ◽

Antibody Responses ◽

Antibody Titres ◽

Adult Volunteers ◽

Representative Member ◽

Heterologous Antibody

SummaryIn a group of 32 adult volunteers given subunit influenza virus vaccine containing 250 international units (i.u.) of A/Victoria/3/75, 250 i.u. of A/Scotland/ 840/74 and 300 i.u. of B/Hong Kong/8/73, there were substantial increases in the geometric mean homologous haemagglutination-inhibiting (HI) antibody titres. There was also substantial boosting of the antibodies to the earlier variants of the Hong Kong (H3N2) series and to a later variant of the Asian (H2N2) series. There was no boosting of antibodies to the A/FM/1/47 strain, a representative member of the H1N1 series, but two individuals showed substantial rises to A/PR/8/34 (H0N1).There were increases in the HI titre of antibodies cross reactive with two recent isolations, A/Texas/1/77, and A/Victoria/35/77, but the majority of vaccinees failed to reach antibody titres likely to be protective against such strains.

Download Full-text

Coronavirus antibody titres in sera of healthy adults and experimentally infected volunteers

Journal of Hygiene ◽

10.1017/s0022172400022294 ◽

1972 ◽

Vol 70 (2) ◽

pp. 235-244 ◽

Cited By ~ 36

Author(s):

A. F. Bradburne ◽

B. A. Somerset

Keyword(s):

General Population ◽

Virus Strain ◽

High Frequency ◽

Haemagglutination Inhibition ◽

Neutralizing Antibody ◽

Antibody Responses ◽

Normal Adult ◽

Apparent Increase ◽

Antibody Titres ◽

Heterologous Antibody

SUMMARYSix coronaviruses isolated in the U.S.A. have been inoculated into volunteers and all produced colds. Between 10 and 20 % of infected volunteers developed heterologous antibody responses after these and other experimental infections with coronaviruses. The haemagglutination-inhibition test with the OC43 virus strain was found to detect antibody rises after infection with a variety of strains.Studies on normal adult sera taken between 1965 and 1970 revealed a high frequency of neutralizing antibody to one strain (229E) and a frequency of HI antibody to strain OC43 which fluctuated from year to year. Complement-fixing antibodies to these two viruses were also found, revealing an apparent increase in the activity of coronaviruses in the general population of the U.K., during the winter of 1968–9.

Download Full-text

Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines

Vaccine ◽

10.1016/j.vaccine.2020.11.041 ◽

2021 ◽

Vol 39 (2) ◽

pp. 402-411

Author(s):

Anu Haveri ◽

Niina Ikonen ◽

Carita Savolainen-Kopra ◽

Ilkka Julkunen

Keyword(s):

Pandemic Influenza ◽

Influenza A ◽

H5n1 Virus ◽

Antibody Responses ◽

Heterologous Antibody

Download Full-text

Absence of heterologous antibody responses in human volunteers after rhinovirus vaccination

Archives of Virology ◽

10.1007/bf01250850 ◽

1969 ◽

Vol 28 (1) ◽

pp. 89-92 ◽

Cited By ~ 11

Author(s):

E. J. Stott ◽

C. Draper ◽

P. B. Stones ◽

D. A. J. Tyrrell

Keyword(s):

Antibody Responses ◽

Human Volunteers ◽

Heterologous Antibody

Download Full-text

Homologous and Heterologous Antibody Responses to Lipopolysaccharide after EnterohemorrhagicEscherichia coliInfection

Microbiology and Immunology ◽

10.1111/j.1348-0421.2004.tb03484.x ◽

2004 ◽

Vol 48 (1) ◽

pp. 27-38 ◽

Cited By ~ 4

Author(s):

Reiko Tsutsumi ◽

Naoko Ichinohe ◽

Osamu Shimooki ◽

Fumiko Obata ◽

Kiomi Takahashi ◽

...

Keyword(s):

Antibody Responses ◽

Heterologous Antibody

Download Full-text

Heterologous Antibody Responses Conferred by A(H3N2) Variant and Seasonal Influenza Vaccination Against Newly Emerged 2016–2018 A(H3N2) Variant Viruses in Healthy Persons

Clinical Infectious Diseases ◽

10.1093/cid/ciz1203 ◽

2019 ◽

Author(s):

Feng Liu ◽

Min Z Levine

Keyword(s):

Public Health ◽

Young Children ◽

Seasonal Influenza ◽

Cross Reactivity ◽

Antibody Responses ◽

Pandemic Preparedness ◽

The Public ◽

Cluster A ◽

Human Vaccine ◽

Heterologous Antibody

Abstract Background Swine origin A(H3N2) variant [A(H3N2)v] viruses continue to evolve and remain a public health threat. Recent outbreaks in humans in 2016–2018 were caused by a newly emerged A(H3N2)v cluster 2010.1, which are genetically and antigenically distinct from the previously predominant cluster IV. To address the public health risk, we evaluated the levels of heterologous cross-reactive antibodies to A(H3N2)v cluster 2010.1 viruses induced from an existing cluster IV A(H3N2)v vaccine and several seasonal inactivated influenza vaccines (IIVs) in adults, elderly individuals, and children. Methods Human vaccine sera and ferret antisera were analyzed by hemagglutination inhibition (HI) and neutralization assays against representative A(H3N2)v viruses from clusters IV and 2010.1 and seasonal A(H3N2) viruses. Results Ferret antisera detected no or little cross-reactivity between the 2 A(H3N2)v clusters or between A(H3N2)v and seasonal A(H3N2) viruses. In humans, cluster IV A(H3N2)v vaccine induced antibodies cross-reactive to cluster 2010.1 viruses in approximately one-third of the 89 adult and elderly vaccinees. Seasonal IIVs did not induce seroprotective antibodies (≥40) to A(H3N2)v viruses in young children, but induced higher antibodies to A(H3N2)v viruses in cluster 2010.1 than those in cluster IV in adults. Conclusions Cluster IV A(H3N2)v vaccine did not provide sufficient heterologous antibody responses against the new 2010.1 cluster A(H3N2)v viruses. Seasonal IIV could not induce seroprotective antibodies to 2010.1 cluster A(H3N2)v viruses in young children, suggesting that young children are still at high risk to the newly emerged A(H3N2)v viruses. Continued surveillance on A(H3N2)v viruses is critical for risk assessment and pandemic preparedness.

Download Full-text